Skip to main content
. Author manuscript; available in PMC: 2017 May 2.
Published in final edited form as: Abdom Radiol (NY). 2016 May;41(5):889–898. doi: 10.1007/s00261-015-0563-0

Fig. 4.

Fig. 4

67-Year-old male with castrate-resistant metastatic prostate cancer. FDG PET maximum intensity projection images before (A, PSA of 223.3 ng/mL) and after (B, PSA of 52.5 ng/mL) chemotherapy show marked decline in metabolic activity of multiple metastatic lesions in response to therapy.